ORIC Pharmaceuticals, Inc. has announced promising preliminary efficacy and safety data from its ongoing Phase 1b trial of ORIC-944. The trial involves combining ORIC-944 with androgen receptor inhibitors in patients with metastatic castration-resistant prostate cancer (mCRPC). The study reported a 59% PSA50 response rate, with a confirmed rate of 47%, and a 24% confirmed PSA90 response rate. PSA responses were consistent across all dose levels and in combination with both apalutamide and darolutamide. The safety profile of the drug combination was compatible with long-term dosing, with most adverse events being Grade 1 or 2. ORIC Pharmaceuticals also announced a $125 million financing, extending its cash runway into the second half of 2027. The company plans to initiate its first global registrational trial in the first half of 2026.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。